Market
Combination of HCB101 and AST-301 to be evaluated first in gastric and breast cancers Both candidates have orphan drug designation for gastric cancer

HankerBio and AstonSci are launching a collaborative research effort on a dual-action immunotherapy targeting solid tumors.
According to BioPharma Asia Pacific on the 27th (local time), HankerBio and AstonSci signed a memorandum of understanding (MOU) for a strategic research collaboration to evaluate a combination regimen of HCB101, a macrophage-targeting immunotherapy, and a therapeutic cancer vaccine candidate.
As the first step in the collaboration, the companies will evaluate HCB101 in combination with AstonSci's lead candidate, AST-301. AST-301 is a HER2-targeted plasmid DNA therapeutic vaccine currently in Phase 2 clinical development.
The companies plan to explore additional combination regimens, including an investigational PD-L1 therapeutic vaccine, to expand the collaboration across different vaccine approaches and immune mechanisms.
HCB101 is an SIRPα-IgG4 Fc fusion protein developed using HankerBio's proprietary FBDB platform. It is designed to block the CD47-SIRPα “don't eat me” signal, restoring macrophage phagocytic activity while minimizing red blood cell toxicity.
The companies aim to combine vaccine-induced adaptive T-cell responses with macrophage-driven innate immune tumor clearance to generate sustained antitumor immunity.
Initial translational research is evaluating HCB101 in combination with AST-301 in breast and gastric cancers. Both candidates have received orphan drug designation from the U.S. Food and Drug Administration (FDA) for gastric cancer, providing a regulatory foundation for potential joint clinical development.
Preclinical and translational assessments will measure antitumor efficacy, macrophage reactivation, T-cell dynamics and antigen spreading beyond HER2.
Scott Liu, founder and CEO of HankerBio, said, “Cancer vaccines have entered a new era, but teaching the immune system to recognize cancer is only part of the challenge. I believe the next breakthrough lies in connecting immune education with immune execution.”
Wonil Kim, chief scientific officer (CSO) of AstonSci, said, “To fully realize the potential of therapeutic cancer vaccines, they need to be combined with immune mechanisms that produce synergistic effects. We can now evaluate how HCB101's macrophage checkpoint blockade complements AST-301's T-cell activation.”
The joint strategy focuses on rapid validation of the mechanism to support potential future joint clinical development. Target indications include HER2-expressing gastric, gastroesophageal junction, breast and colorectal cancers.
Executives from both companies plan to attend Bio-Europe 2026, taking place April 9-11 in Cologne, Germany, to present the scientific rationale for the combination regimen and explore collaboration opportunities with global pharmaceutical companies and investors.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Medtronic to Acquire Contego Medical for $380 Million, Strengthening Carotid Treatment Portfolio

AstraZeneca wins Soliris antitrust lawsuit, with court finding no patent abuse

Alphabet Subsidiary Isomorphic Raises $5 Billion for AI Drug Development

Google Subsidiary Isomorphic Raises Another $5 Billion in Funding in Six Months

Lilly invests $7.9 billion in cancer-targeting technology company in fourth deal in 6 weeks

Samsung Biologics Completes 2.665 Trillion Won Rights Offering; New Shares to List Nov. 30